Equity capital markets

D.A. Davidson Names Eric Stetler as Head of M&A, Investment Banking

Retrieved on: 
Wednesday, April 10, 2024

Davidson & Co. announced today that its Investment Banking business has appointed Eric Stetler, Managing Director, to Head of M&A.

Key Points: 
  • Davidson & Co. announced today that its Investment Banking business has appointed Eric Stetler, Managing Director, to Head of M&A.
  • Davidson Investment Banking in addition to his Machinery & Equipment sector coverage.
  • We are thrilled to have Eric embrace these additional responsibilities while continuing his industrial sector coverage.”
    Based in Chicago, Stetler joined D.A.
  • Davidson Investment Banking is a leading full-service investment bank that offers comprehensive financial advisory and capital markets expertise.

PACS Group, Inc. Announces Pricing of Its Upsized Initial Public Offering

Retrieved on: 
Thursday, April 11, 2024

PACS Group, Inc. (“PACS” or the “Company”) today announced the pricing of its upsized initial public offering of 21,428,572 shares of its common stock being sold by the Company at a public offering price of $21.00 per share, for total gross proceeds of approximately $450 million, before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • PACS Group, Inc. (“PACS” or the “Company”) today announced the pricing of its upsized initial public offering of 21,428,572 shares of its common stock being sold by the Company at a public offering price of $21.00 per share, for total gross proceeds of approximately $450 million, before deducting underwriting discounts and commissions and offering expenses.
  • In addition, certain selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 3,214,284 shares of the Company’s common stock at the initial public offering price, less underwriting discounts and commissions.
  • PACS will not receive any proceeds from any sale of shares by the selling stockholders.
  • Citigroup, J.P. Morgan and Truist Securities are acting as lead book-running managers for the offering.

FIFTH WALL NAMES JEREMY FOX & G.M. NICHOLAS VIK CO-PRESIDENTS

Retrieved on: 
Tuesday, April 23, 2024

NEW YORK, April 23, 2024 /PRNewswire/ -- Fifth Wall—the largest asset manager focused on improving, future-proofing, and decarbonizing the built world—announced that Jeremy Fox and G.M. Nicholas "Magnus" Vik have been appointed the Firm's Co-Presidents, a new position, to help guide the company through its next phase of transformational growth.

Key Points: 
  • In tandem with serving as Co-President, alongside Fox, Vik has been appointed Fifth Wall's Chief Operating Officer.
  • Prior to joining Fifth Wall, Vik was Director of Strategy & Finance and a founding member at Renew Health.
  • "In their time at Fifth Wall, Jeremy and Magnus have proven to be highly valuable assets to our team, our Limited Partners, and our Portfolio Companies," said Brad Greiwe , Chairman of Fifth Wall.
  • In addition to Fox and Vik's appointment to Co-Presidents, Fifth Wall has also elevated five other senior team members.

Contineum Therapeutics Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, April 5, 2024

All of the shares are being offered by Contineum.

Key Points: 
  • All of the shares are being offered by Contineum.
  • The gross proceeds to Contineum from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Contineum, are expected to be $110.0 million.
  • In addition, Contineum has granted the underwriters a 30-day option to purchase up to an additional 1,031,250 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions.
  • Goldman Sachs & Co. LLC, Morgan Stanley, Stifel, and RBC Capital Markets are acting as joint book-running managers for the offering.

Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering

Retrieved on: 
Tuesday, April 2, 2024

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deducting underwriting discounts and commissions and offering expenses.
  • The accompanying common warrants will be immediately exercisable for shares of common stock or pre-funded warrants in lieu thereof, and will expire on the twelve-month anniversary of the date of issuance.
  • All of the shares of common stock, accompanying common warrants and pre-funded warrants are being offered by Gritstone bio.
  • The securities are being offered by Gritstone bio pursuant to a registration statement on Form S-3 (File No.

Gritstone bio Announces Proposed Public Offering

Retrieved on: 
Monday, April 1, 2024

All of the shares of common stock, pre-funded warrants and accompanying common warrants are being offered by Gritstone bio.

Key Points: 
  • All of the shares of common stock, pre-funded warrants and accompanying common warrants are being offered by Gritstone bio.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • TD Cowen and Evercore ISI are acting as the joint book-running managers for the proposed offering.
  • The securities are being offered by Gritstone bio pursuant to a registration statement on Form S-3 (File No.

ATS Announces C$163 Million Secondary Offering of Common Shares

Retrieved on: 
Wednesday, March 27, 2024

The Offering is expected to close on or about April 3, 2024 (the “Closing”).

Key Points: 
  • The Offering is expected to close on or about April 3, 2024 (the “Closing”).
  • All of the shares in the Offering will be sold by the Selling Shareholder.
  • The Company will not receive any proceeds from the sale of the Shares by the Selling Shareholder.
  • The Selling Shareholder notes, “As a long-time investor in ATS, Mason remains committed to the Company as reflected by our significant ownership stake.

Marex Group plc Announces Filing of Registration Statement for Proposed Initial Public Offering

Retrieved on: 
Tuesday, March 26, 2024

NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Marex Group (“Marex”), the diversified global financial services platform, today announces that it has publicly filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares.

Key Points: 
  • NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Marex Group (“Marex”), the diversified global financial services platform, today announces that it has publicly filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares.
  • The timing of the offering, number of shares to be offered and the price range for the proposed offering have not yet been determined.
  • Barclays, Goldman Sachs & Co. LLC, Jefferies, and Keefe, Bruyette & Woods, a Stifel Company, are acting as joint lead book-running managers for the proposed offering.
  • A registration statement relating to these securities has been filed with the SEC but has not yet become effective.

Nkarta Announces Pricing of $240 Million Underwritten Offering

Retrieved on: 
Monday, March 25, 2024

Gross proceeds to Nkarta from this offering are approximately $240.1 million, before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • Gross proceeds to Nkarta from this offering are approximately $240.1 million, before deducting underwriting discounts and commissions and offering expenses.
  • The offering is expected to close on or about March 27, 2024, subject to customary closing conditions.
  • All securities in the offering are to be issued and sold by Nkarta.
  • The offering was made only by means of a prospectus supplement and accompanying prospectus describing the terms of the offering.

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

Retrieved on: 
Tuesday, March 19, 2024

The size of the offering was increased by $100 million subsequent to the initial announcement of the offering.

Key Points: 
  • The size of the offering was increased by $100 million subsequent to the initial announcement of the offering.
  • The gross proceeds to Madrigal from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $600 million.
  • Madrigal has granted the underwriters of the offering a 30-day option to purchase up to an additional 346,153 shares of common stock from the company at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about March 21, 2024, subject to the satisfaction of customary closing conditions.